A QSAR STUDY COMPARING THE CYTOTOXICITY AND DNA TOPOISOMERASE-II INHIBITORY EFFECTS OF BISDIOXOPIPERAZINE ANALOGS OF ICRF-187 (DEXRAZOXANE)

被引:113
作者
HASINOFF, BB
KUSCHAK, TI
YALOWICH, JC
CREIGHTON, AM
机构
[1] UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261
[2] UNIV PITTSBURGH,PITTSBURGH CANC INST,PITTSBURGH,PA 15261
[3] ST BARTHOLOMEWS HOSP,COLL MED,DEPT REPROD PHYSIOL,MED CHEM LAB,LONDON EC1A 7BE,ENGLAND
关键词
ICRF-187; DEXRAZOXANE; ICRF-193; BISDIOXOPIPERAZINE; TOPOISOMERASE II; INHIBITION;
D O I
10.1016/0006-2952(95)00218-O
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of twelve structurally related bisdioxopiperazines that included ICRF-187 (dexrazoxane), ICRF-159 (razoxane), ICRF-193, and ICRF-154 were examined both for their ability to inhibit the growth of Chinese hamster ovary (CHO) cells and their ability to inhibit the catalytic activity of mammalian DNA topoisomerase II. The bisdioxopiperazines exhibited a wide range in both growth inhibitory effects (30,000-fold), and in their ability to inhibit the catalytic activity of topoisomerase II (150-fold). The cytotoxicity of the bisdioxopiperazines toward CHO cells was highly correlated (correlation coefficient r = 0.86, P = 0.0003) with their inhibition of the catalytic activity of DNA topoisomerase II. This result strongly suggests that DNA topoisomerase Ii is the functional target of the bisdioxopiperazines. The stereoisomers (+)-ICRF-I87 and (-)-ICRF-186 were observed to be equally cytotoxic and equally inhibitory toward DNA topoisomerase II, This result indicates that the bisdioxopiperazine binding site on DNA topoisomerase II is large enough or flexible enough to accommodate either form of the drug. The strongly metal-ion binding fully rings-opened hydrolysis product of ICRF-187, ADR-925, demonstrated no measurable inhibitory activity toward DNA topoisomerase II or cytotoxicity toward CHO cells.
引用
收藏
页码:953 / 958
页数:6
相关论文
共 38 条
[1]   EFFECT OF (+ OR -) 1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL) PROPANE (ICRF 159) ON LIVER METASTASES FROM A HAMSTER LYMPHOMA [J].
ATHERTON, A .
EUROPEAN JOURNAL OF CANCER, 1975, 11 (06) :383-&
[2]   SURAMIN IS AN INHIBITOR OF DNA TOPOISOMERASE-II INVITRO AND IN CHINESE-HAMSTER FIBROSARCOMA CELLS [J].
BOJANOWSKI, K ;
LELIEVRE, S ;
MARKOVITS, J ;
COUPRIE, J ;
JACQUEMINSABLON, A ;
LARSEN, AK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :3025-3029
[3]   INHIBITION OF TYPE-II TOPOISOMERASE BY FOSTRIECIN [J].
BORITZKI, TJ ;
WOLFARD, TS ;
BESSERER, JA ;
JACKSON, RC ;
FRY, DW .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (21) :4063-4068
[4]   THE ONE-RING OPEN HYDROLYSIS PRODUCT INTERMEDIATES OF THE CARDIOPROTECTIVE AGENT ICRF-187 (DEXRAZOXANE) DISPLACE IRON FROM IRON-ANTHRACYCLINE COMPLEXES [J].
BUSS, JL ;
HASINOFF, BB .
AGENTS AND ACTIONS, 1993, 40 (1-2) :86-95
[5]   WHEN GOOD ENZYMES GO BAD - CONVERSION OF TOPOISOMERASE-II TO A CELLULAR TOXIN BY ANTINEOPLASTIC DRUGS [J].
CORBETT, AH ;
OSHEROFF, N .
CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (05) :585-597
[6]  
CREIGHTON AM, 1969, NATURE, V22, P384
[7]  
CREIGHTON AM, 1979, 6TH P INT S MED CHEM, P281
[8]  
CREIGHTON AM, 1974, Patent No. 1374979
[9]  
CREIGHTON AM, 1971, Patent No. 1234935
[10]   ALTERED CATALYTIC ACTIVITY OF AND DNA CLEAVAGE BY DNA TOPOISOMERASE II FROM HUMAN-LEUKEMIC CELLS SELECTED FOR RESISTANCE TO VM-26 [J].
DANKS, MK ;
SCHMIDT, CA ;
CIRTAIN, MC ;
SUTTLE, DP ;
BECK, WT .
BIOCHEMISTRY, 1988, 27 (24) :8861-8869